Valuation: Alzinova AB

Market Cap 211M 22.12M 19.21M 17.91M 16.45M 31.12M 2.1B 31.46M 82.54M 1.05B 83.08M 81.26M 3.49B P/E 2026 *
-3.86x
P/E 2027 * -2.74x
Enterprise Value 195M 20.45M 17.75M 16.55M 15.21M 28.76M 1.94B 29.07M 76.29M 972M 76.78M 75.1M 3.22B EV / Sales 2026 *
6.22x
EV / Sales 2027 * -
Free-Float
82.23%
Yield 2026 *
-
Yield 2027 * -
1 day-4.93%
1 week+1.17%
Current month-10.17%
1 month+110.51%
3 months+137.63%
6 months+35.32%
Current year+25.69%
1 week 0.93
Extreme 0.93
1.23
1 month 0.48
Extreme 0.48
1.61
Current year 0.38
Extreme 0.382
1.61
1 year 0.38
Extreme 0.382
2.28
3 years 0.38
Extreme 0.382
4.62
5 years 0.38
Extreme 0.382
8.7
10 years 0.38
Extreme 0.382
44.9
Manager TitleAgeSince
Chief Executive Officer 59 01/10/2024
Chief Operating Officer 54 17/08/2011
Director of Finance/CFO 57 27/03/2024
Director TitleAgeSince
Director/Board Member 61 01/09/2015
Director/Board Member 69 01/01/2018
Director/Board Member - 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-4.93%+1.17%-29.69%-69.22% 22.12M
-0.68%-0.68%-1.63%+12.86% 48B
+6.03%+5.22%+420.33%+519.87% 41.13B
-2.21%-6.07%+24.87%+5.20% 37.56B
+2.94%-2.25%+6.15%+59.69% 35.91B
+1.98%+4.74%+12.19%+41.37% 29.86B
+0.47%-3.87% - - 16.12B
+0.31%+0.72%+32.99%+122.25% 16.05B
+1.59%+0.44%+3.43%+16.80% 13.76B
-0.98%-12.98%-4.82%-38.09% 12.1B
Average +0.45%+0.66%+51.53%+74.53% 25.05B
Weighted average by Cap. +1.28%+1.56%+82.11%+116.49%

Financials

2026 *2027 *
Net sales 31.35M 3.28M 2.85M 2.66M 2.44M 4.62M 312M 4.67M 12.26M 156M 12.33M 12.06M 517M -
Net income -3.2M -335K -291K -271K -249K -472K -31.89M -477K -1.25M -15.94M -1.26M -1.23M -52.82M -50.35M -5.28M -4.58M -4.27M -3.92M -7.42M -502M -7.5M -19.68M -251M -19.81M -19.38M -831M
Net Debt -16M -1.68M -1.46M -1.36M -1.25M -2.36M -159M -2.38M -6.25M -79.71M -6.3M -6.16M -264M -19M -1.99M -1.73M -1.61M -1.48M -2.8M -189M -2.83M -7.43M -94.66M -7.48M -7.31M -314M
Logo Alzinova AB
Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimer’s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric Aβ that damages brain synapses.
Employees
7
Date Price Change Volume
04/08/26 SEK 1.042 -4.93% 4,290,961
03/08/26 SEK 1.096 -5.52% 5,527,250
31/07/26 SEK 1.160 +14.17% 7,413,903
30/07/26 SEK 1.016 +3.89% 2,344,913
29/07/26 SEK 0.9780 -5.05% 5,308,647

Annual profits - Rate of surprise